Psychedelics Seek to Emulate Cannabis Rise to Social Acceptance #100954

[ad_1]

For example, earlier this year, billionaires attending the World Economic Forum in Davos heard a pitch from a company developing a psychedelic drug to treat opioid addiction. In a report by Bloomberg from earlier this January, the Company Atai, backed by billionaire investor Peter Thiel, and partner DemeRx Inc., are preparing for a mid-stage trial of a synthetic form of the substance, called ibogaine, for treatment of drug addiction. Interest in ...
Continue Reading →

Mind Medicine (MindMed) Inc adds new principal investigator and Swiss trial site as it expands Phase 2 study of microdosing LSD for adult ADHD

[ad_1]

The Reno-based neuro-pharmaceutical firm’s microdosing division is expanding its slate of research and clinical trials

Mind Medicine (MindMed) Inc (NEO:MMED) () said it had appointed a world-leading psychedelics researcher as principal investigator for the first ever Phase 2a proof-of-concept clinical trial assessing lysergic acid diethylamide (LSD) to treat attention deficit hyperactivity disorder (ADHD) in adults.

It comes as the Reno-based neuro-pharmaceutical firm’s microdosing division, which is assessing consuming very low, sub-hallucinogenic doses of psychedelic ...

Continue Reading →

Investing in Ibogaine Stocks

[ad_1]

Two weeks ago, I lost another friend to addiction.

This is the second one this year.

The first was a friend of mine who was a heroin addict and overdosed, after being clean for more than a year.

The second, and most recent, was Nick, who I’ve known for about 20 years. 

We’re still waiting on the toxicology report to find out what happened, but I’m certain prescription opioids were involved, as I know he’s ...

Continue Reading →
Page 15 of 50 «...101314151617...»
UA-77446339-1